Pacific Biosciences Of California (PACB) Operating Expenses (2010 - 2026)

Pacific Biosciences Of California has reported Operating Expenses for 17 years, with the latest figure at $57.2 million in Q2 2026.

• On a quarterly basis, Operating Expenses fell 3.84% year-over-year to $57.2 million in Q2 2026; TTM through Jun 2026 was $191.0 million, a 73.63% decrease from a year earlier, with the FY2025 full-year figure at $599.6 million, up 17.21% from the prior year.
• Operating Expenses was $57.2 million for Q2 2026 at Pacific Biosciences Of California, up from $21.2 million in the prior quarter.
• The five-year high for Operating Expenses was $427.6 million in Q1 2025, with the low at $21.2 million in Q1 2026.
• Average Operating Expenses over 5 years is $107.4 million, with a median of $90.2 million recorded in 2022.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses surged 634.72% in 2022, then sank 95.04% in 2026.
• Over 5 years, Operating Expenses stood at $92.2 million in 2022, then climbed by 5.31% to $97.1 million in 2023, then surged by 67.92% to $163.1 million in 2024, then slumped by 64.58% to $57.8 million in 2025, then declined by 0.89% to $57.2 million in 2026.
• The last three Operating Expenses figures came in at $57.2 million (Q2 2026), $21.2 million (Q1 2026), and $57.8 million (Q4 2025), per Business Quant data.